Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
During crisis, patients presented with less acute coronary syndrome (ACS - 45.5% vs. 39.9%, p < 0.001).
|
29601956 |
2020 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Information on the relationship between circulating cholesteryl ester transfer protein (CETP) levels and coronary heart disease (CHD) incidence (and also, therefore, acute coronary syndrome [ACS]) is conflicting.
|
31504738 |
2020 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe the incidence, timing, and characteristics of stent thrombosis and its consequences in patients with atrial fibrillation (AF) in the AUGUSTUS trial<sup>1</sup> who received a coronary stent during their qualifying admission (acute coronary syndrome [ACS] or elective percutaneous coronary intervention [PCI]) and the randomized treatment effects of low-dose aspirin (compared with placebo) and apixaban (compared with vitamin K antagonist [VKA]) on the risk of stent thrombosis.
|
31707833 |
2020 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the MAIN-COMPARE study including 2,240 patients with LMCA disease treated with PCI (n = 1102) or CABG (n = 1138), we examined interaction between acuity of clinical presentation (acute coronary syndromes [ACS] or non-ACS) and revascularization strategy on 10-year outcomes.
|
31655415 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prospective cohort study of 75 stable patients with CAD and 3 differing clinical profiles (stable angina [SA]; remote myocardial infarction [MI]; repetitive acute coronary syndrome [ACS]) and 25 controls without angiographic CAD, each with 15 hs-cTnT measurements over 1 year.
|
31679620 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All patients admitted for acute coronary syndrome at Östersund hospital between 2010-2014 were screened for the randomized controlled NAILED-ACS trial.
|
31427637 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetes and outcomes following guided de-escalation of antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: a pre-specified analysis from the randomised TROPICAL-ACS trial.
|
31012853 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methods and Results The TRANSLATE -ACS (Treatment with ADP Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) study included 11 108 MI patients treated with percutaneous coronary intervention and discharged alive on a P2Y<sub>12</sub> inhibitor from 233 US hospitals.
|
31070112 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methods and Results To understand the cost drivers during hospitalization for acute MI and in the following year, we prospectively studied 11 969 patients with acute MI undergoing percutaneous coronary intervention at 233 US hospitals (2010-2013) from the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) registry.
|
30975005 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among them, 10 628 patients (1.9%), including 6780 (1.2%) with acute coronary syndrome ( ACS ) and 3848 (0.7%) with stable coronary artery disease, were ≥90 years of age.
|
30791799 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Between November 2014 and November 2016, we collected health-related quality of life data among 1261 participants in the ACS QUIK trial (Acute Coronary Syndrome Quality Improvement in Kerala).
|
30755027 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, it is not easy to make a complete changeover to NOACs in real-world clinical practice because NOACs still have challenges in specific patient populations (eg, Asian patients, NVAF patients presenting with acute coronary syndrome [ACS], dialysis patients with NVAF, patients with cancer-associated VTE, etc.).
|
31632045 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analyses were repeated stratified by whether or not the procedure had been performed in the setting of an acute coronary syndrome ( ACS ).
|
30642222 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 1,121,359 cases (103,887 EVT cases for critical limb ischemia [CLI] or intermittent claudication and 1,017,472 PCI cases for acute coronary syndrome [ACS] or stable angina) were analyzed.
|
31730004 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Background The prognostic significance of obstructive sleep apnea ( OSA ) in patients with acute coronary syndrome ( ACS ) in the contemporary era is unclear.
|
30636505 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Conflicting evidence exists about the impact of marital status on the outcomes of patients with acute coronary syndrome ( ACS ).
|
31266391 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Dialysis patients had more comorbidities than nondialysis patients and higher rates of complications including in-hospital mortality (3.3% vs. 1.5%, respectively, in the acute coronary syndrome [ACS] cohort, 0.2% vs. 0.1% in the non-ACS cohort) and bleeding complications requiring blood transfusion (1.1% vs. 0.4% in ACS, 0.5% vs. 0.2% in non-ACS).
|
30467967 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study.
|
29437596 |
2018 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Status of the Epicardial Coronary Arteries in Non-ST Elevation Acute Coronary Syndrome in Patients with Mechanical Prosthetic Heart Valves (from the TROIA-ACS Trial).
|
29970239 |
2018 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients were hierarchically classified into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and secondary prevention), atherosclerotic CV disease (including recent acute coronary syndrome [ACS], chronic coronary heart disease, stroke, and peripheral arterial disease), and diabetes mellitus (DM) alone.
|
29499359 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methods and Results Included were patients with ACS enrolled in the biennial Acute Coronary Syndrome Israeli Surveys ( ACSIS ) between 2008 and 2016.
|
30371188 |
2018 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Extracted data included baseline cardiac status, dosimetric parameters to the whole heart (WH) and cardiac substructures, and the development of post-CRT symptomatic cardiac events (acute coronary syndrome [ACS], arrhythmia, pericardial effusion, pericarditis, and congestive heart failure [CHF]).
|
29883836 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk stratification after percutaneous coronary intervention (PCI) is mainly based on demographics and clinical presentation (stable coronary artery disease [CAD] vs. acute coronary syndromes [ACS]).
|
30041804 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
(Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome [ACS] [VAMPIRE3]; NCT01460966).
|
30077678 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The TRANSLATE-ACS study (Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome) assessed employment status at baseline and 1 year among 9319 patients with MI (mean age, 60.8 years; SD, 11.3; 27.3% women) enrolled at 233 US hospitals.
|
29895612 |
2018 |